Back to list

PBAC recommends Dupixent® for the treatment of severe atopic dermatitis in patients 12 years and above

Tuesday 05, May 2020

Sydney – 24 April 2020 – Dupixent® (dupilumab), a first in class biologic therapy, has

been recommended for listing on the Pharmaceutical Benefits Scheme for the treatment of

eligible patients (12 years and above) with severe atopic dermatitis who have had an

inadequate response to topical corticosteroids and/or topical calcineurin inhibitors

(TCS/TCI)*.1

Sanofi Genzyme Australia and New Zealand Head of Medical, Dr Paul King thanked the

PBAC for their recommendation and acknowledged the extensive feedback provided by

clinicians, patient support groups and individual patients who responded to the PBAC’s call

for consumer comments about Dupixent prior to the March meeting.

“We recognise the debilitating impact of severe atopic dermatitis on the lives of many

Australians and the incredibly challenging environment we are all addressing as a result of

COVID-19.

“As a company we remain committed to supporting clinicians who have patients who are

receiving Dupixent through our early access scheme and look forward to working with the

Federal Government to support the earliest possible PBS listing for all eligible patients,” he

said.

Dr King assured clinicians that the company will continue to provide Dupixent to patients

who are receiving the medicine through the company’s early access scheme, until the

medicine is added to the PBS. The scheme is no longer open for new patients.

Attachment
Read the full article here